Introduction
The genome of multiple myeloma (MM) is characterized by primary translocations in approximately 40% of newly diagnosed patients that are considered initiating events and involve rearrangements of the immunoglobulin heavy chain (IGH) locus on 14q32. 1 The partners of these rearrangements include 11q (CCND1, 15%), 4p (FGFR3 and MMSET, 10%), 16q (MAF, 2-3%), 20q (MAFB, 1%), and 6q (CCND3, 1%). These rearrangements result in placement of the IGH superenhancers next to a partner oncogene, resulting in its overexpression. 2 The rearrangements predominantly occur in the switch regions 5' of the constant regions in the IGH locus, where a high concentration of activation-induced cytidine deaminase (AID) binding motifs are found. Normally, AID binds to the switch regions leading to class switch recombination, resulting in antibody isotype switching. 3 However, abnormal breaks in the switch regions, resulting from AID activity, result in IGH translocations. 4 Secondary translocations involving MYC, located on 8q24.21, also occur in MM and are associated with disease progression and increased expression of MYC. [5] [6] [7] [8] MYC encodes a transcriptional regulator and has been shown to be involved in proliferation, differentiation, protein synthesis, apoptosis, adhesion, DNA repair, chromosomal instability, angiogenesis, and metastasis. [9] [10] [11] [12] [13] Translocations and high expression of MYC are associated with poor outcome, especially in MM where it is a marker of aggressive disease. 5, 14 MYC can be deregulated by a range of different mechanisms including chromosomal rearrangement, 5, 6 copy-number gain/amplification, 15, 16 protein stabilization, 17 via secondary messengers involved in MYC transcription 18 or miRNA such as PVT1. 19, 20 The frequency of MYC rearrangements seen in newly diagnosed MM (NDMM) varies from 15% to 50%, and is dependent on the method used to identify it. 5, 6, 21, 22 The data are consistent with MYC rearrangements being rare in the asymptomatic stages, such as monoclonal gammopathy of uncertain significance and smoldering myeloma, 21 and increases as the disease progresses, with a high incidence (>80%) in myeloma cell lines. [22] [23] [24] MYC rearrangements are not only seen in MM, but are also frequent in lymphomas, where they have been extensively studied. 25, 26 In Burkitt's lymphoma and diffuse large B-cell lymphoma t (8;14) , rearrangements between IGH and MYC have also been shown to result from abnormal class switch recombination. 27 The relevance of AID in these rearrangements is supported by data from IL-6 transgenic mice which also develop MYC/IGH rearrangements in B cells. Rearrangements, however, do not occur if the mice are also deficient in AID, indicating that class switch recombination via AID is key in generating these rearrangements. 4, 28 In MM, while karyotypic abnormalities similar to those observed in Burkitt's lymphoma are seen, variant structures can also be detected, suggesting that the mechanism of rearrangement in MM may not be identical to that in lymphoma. 29 Indeed, MYC rearrangements are not considered to be predominantly primary translocations in MM, as they often develop at later stages of the disease; 22 whereas in lymphoma they are considered to be primary events. 27 We and others have previously shown that MYC translocations result in the juxtaposition of immunoglobulin loci super-enhancers to MYC resulting in its overexpression. 6, 30 However, the details of breakpoint locations, the presence of copy-number abnormalities, and the chromatin landscape of the rearrangement have not been well-characterized. In the present study, we analyzed a large dataset of 1,267 NDMM patients to determine the genomic architecture of MYC rearrangements and their effect on the expression of this proto-oncogene.
Methods

Patients' samples and next generation sequencing
A total of 1,267 NDMM patients were included in this study after giving informed consent and the study was approved by the Institutional Review Board at the University of Arkansas for Medical Sciences. Plasma cells were isolated from bone marrow aspirates by magnetic-activated cell sorting using CD138 + marker, AutoMACS Pro (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) or Robosep (STEMCELL Technologies, Vancouver, BC, Canada). DNA from peripheral blood was used as a control sample for each patient to exclude germline variants. Three pairedend read sequencing platforms were combined without overlapping patients: targeted sequencing, whole exome sequencing, and low depth, long insert whole genome sequencing (Online Supplementary Methods). Additional expression data were available through either gene expression microarrays (Affymetrix, Santa Clara, CA, USA) or RNA-sequencing. An overall summary of methods, number of patients and external datasets are shown in Online Supplementary Figure S1 . Patients' characteristics are summarized in Online Supplementary Table S1 and MYC region capture is illustrated in Online Supplementary Figure S2 .
Patient-derived xenografts
Patient-derived xenografts were generated by passaging primary patient CD138 + selected cells through the previously described SCID-rab myeloma mouse model. 31 Tumors were dissected from the mouse, and pieces dispersed into a single cell population using a Kontes disposable tissue grinder. Cells were filtered through a 70 mm sterile filter, washed twice in PBS, treated with red cell lysis buffer, washed twice more, and treated immediately with Annexin V-coated magnetic beads (Miltenyi Biotec), resulting in a population of cells with a viability >95%, as checked by flow cytometry. Passaged cells underwent CD138 + selection before being processed for 10x Genomics whole genome sequencing, RNA-sequencing, and chromatin immunoprecipitation-sequencing (ChIP-seq).
Chromatin immunoprecipitation-sequencing
Chromatin immunoprecipitation-sequencing was performed on the myeloma cell lines KMS11 and MM.1S as well as a PDX sample with an MYC rearrangement identified by whole genome sequencing. 1x10 7 cells per mark were fixed in a 1% formaldehyde solution, followed by the addition of glycine to a final concentration of 0.125 M. Cells were washed and resuspended in PBS containing 0.5% lgepal with 1% PMSF, before being pelleted and frozen at -80oC. ChIP-seq for the histone marks H3K4me1, H3K4me3, H3K9me3, H3K27me3, H3K27Ac, and H3K36me3 (Active Motif, Carlsbad, CA, USA), as well as the super-enhancer proteins BRD4 and MED1 (Bethyl, Montgomer, TX, USA), and the transcription factor MYC (Santa Cruz Biotechnology, Dallas, TX, USA) were performed by Active Motif. Controls without antibody input were performed to ensure data quality.
Data analysis
Data analysis was performed as described previously, with minor differences between sequencing modalities. 32 
Data access
Sequencing data have been deposited in the European Genomic Archive under the accession numbers EGAS00001001147, EGAS00001002859, or at dbGAP under Accession phs000748.v5.p4.
Results
MYC rearrangements are usually present as inter-chromosomal translocations, co-occur with secondary genetic events, and are associated with shorter survival in non-hyperdiploid cases
We examined a set of 1,267 NDMM patient samples that had undergone either whole genome sequencing, exome sequencing, or targeted sequencing, of which the latter two methods involved capture of 2.3 Mb and 4.5 Mb, respectively, surrounding the MYC locus. Structural abnormalities involving the region surrounding MYC, including translocations, inversions, tandem-duplications and deletions, were detected in 36.0% (456 of 1,267) of NDMM samples. Of these 456, 56.6% (258 of 456) had only a translocation, and 30.0% (137 of 456) had only an intrachromosomal rearrangement. In 13.4% (61 of 456), both translocation and intra-locus rearrangement were present.
Non-synonymous MYC mutations were rarely detected (0.7%, 9 of 1,264) (Online Supplementary Table S2 ).
The frequency of 8q24 abnormalities was significantly increased across International Scoring System (ISS) stages (I: 28.6%, II: 37.5%, III: 41.6%; P<0.001), and were higher in the International Myeloma Working Group (IMWG) high-risk (34.6%) and standard-risk (28.1%) groups than in the low-risk group (23.6%; P<0.05). The association of 8q24 abnormalities with these negative prognostic factors may suggest a worse outcome of patients with 8q24 abnormalities; however, analysis of this did not confirm the assumption in this dataset (Online Supplementary Figure  S4A ). In addition, 8q24 abnormalities were associated with lower, rather than higher, NF-κB pathway activation (Online Supplementary Figure S3 ). Additional analysis, however, showed a significant effect of 8q24 abnormalities within the non-hyperdiploid sub-group ( Figure 1A ).
Translocations were found in 25.2% (319 of 1,267) of MMEJ drives 8q24 rearrangements in myeloma haematologica | 2020; 105(4) 1057 , and 2.5% (8 of 319), respectively. However, the number of chromosomes detected as being affected by rearrangements involving MYC was dependent on the sequencing capture method used, as rearrangements involving five or more chromosomes were detected only by whole genome sequencing (Online Supplementary Tables  S3 and S4 ). These data demonstrate that MYC is affected through chromoplexy, where three or more loci are involved in rearrangements in 9.6% (121 of 1,267) of NDMM or 26.5% (121 of 456) of samples with MYC abnormalities.
IGH-MYC translocation breakpoints have a distinct distribution compared to primary translocations and involve recurrent partners with known super-enhancers
A total of 149 chromosomal loci were found to be involved in MYC translocations ( Figure 2A and Online Supplementary Tables S5 and S6 ). Six translocation partners were found in at least ten cases and were the immunoglobulin loci, IGH (63 of 1,253, 5.0%), IGL (63 of 1,253, 5.0%), IGK (26 of 1,253, 2.1%), and also TXNDC5/BMP6 on chromosome 6 (34 of 1,253, 2.7%), FAM46C on chromosome 1 (20 of 1,253, 1.6%), and FOXO3 on chromosome 6 (14 of 1,253, 1.1%) (Online Supplementary Table S5 ). Each of these non-Ig loci was confirmed to contain highly-expressed genes in MM using haematologica | 2020; 105(4) RNA-sequencing data, being present in >95% of patients with log 2 normalized counts >10. All of the loci except for IGK had super-enhancers previously identified in the MM.1S cell line; 67.2% (205 of 305) of cases with noncomplex translocation (5 or less loci involved) had at least one of these super-enhancers involved in the translocation. Another five partners were present in 5-10 cases, three of which overlapped with the highly-expressed genes FCHSD2, FBXW7 and SERTAD2, which are associated with known super-enhancers. 30 Interestingly, 13 samples had complex MYC translocations with more than one of these super-enhancers. In addition, eight samples had rearrangements involving IGH, MYC and CCND1, and four samples had rearrangements with IGH, MYC and MAF, indicating that they may occur as primary events early in the disease process. All oncogenes involved in these translocations show high expression (Online Supplementary Figure S5 ). This targeting of multiple oncogenes may explain worse survival in patients with complex MYC translocations ( Figure 1B ). Ig loci were involved in 47.9% (146 of 305) of cases with an MYC translocation and were not associated with significantly higher MYC expression ( Figure 3B and Online Supplementary Figure S6B ) or patients' survival (Online Supplementary Figure S4D ) compared to samples involving other super-enhancer-associated genes. In six cases, an IGH translocation occurred together with one of the lightchain immunoglobulin loci, but no sample involved both light chain loci. Within the Ig translocation groups, patients with IGL partners showed significantly worse outcome in comparison to IGH (P<0.05), other non-Ig translocations (P<0.01), and cases without MYC translocations (P<0.001) ( Figure 1C ).
Analysis of the breakpoints at the IGH locus indicated a different pattern of MYC rearrangements to that of the primary Ig translocations. The primary translocations involving t(4;14), t(6;14), t(11;14), t(14;16), and t (14;20) have breakpoints clustered around the constant switch regions where AID motifs are concentrated. However, the MYC translocations do not share this pattern and are dispersed across the constant region, showing no association with AID motif clusters. This indicates that the MYC translocations are likely to be independent of AID and occur in a manner that is distinct from that of the primary translocations ( Figure 4A and B).
MYC breakpoints show evidence of recombination through microhomology
It is known that class switch recombination breakpoints in B cells occur through AID and non-homologous end joining (NHEJ), resulting in blunt ended DNA being ligated together. 33 As the MYC breakpoints identified here do not align to switch regions, and are presumably not mediated by AID, we examined the aligned breakpoints to determine if they were constructed through blunt ended joining or other mechanisms. In comparison to re-aligned t(4;14), t(6;14), t(11;14), t(14;16), and t(14;20) breakpoints, which are mediated by AID and NHEJ, the MYC breakpoints had significantly fewer blunt ended rearrangements (54.1% vs. 27.7%; P<0.001) and significantly more rearrangements with at least two nucleotides of homology (25.4% vs. 45 .8%) between the chromosomes ( Figure 4C ). Homologous sequences between chromosomes of up to 12 nts were found. Representative alignments of rearrangements are shown in the Online Supplementary Appendix. These homologous sequences are representative of microhomology-mediated end joining (MMEJ), which is a mechanism more common to all secondary translocation events ( Figure 4C ).
8q24 breakpoints occur in three hotspots and are associated with open chromatin markers
Breakpoints were determined in a region covering up to 2.5 Mb from MYC and were categorized by the type of rearrangement. Three clusters of chromosomal breakpoints related to translocations, inversions, deletions and tandem-duplications were identified in the region chr8:126.0-131.0 Mb ( Figure 5 ).
Translocation breakpoint hotspots were located in two 310 kb regions: one around MYC (chr8:128.6-129.0 Mb) and one telomeric of MYC (chr8:129.1-129.4 Mb). When examining all translocations, 28.2% were centered around the first hotspot and 46.6% around the second hotspot. However, there was an enrichment of Ig part-ner breakpoints at the second hotspot (55.3%) compared to first hotspot (18.9%), which was not so pronounced with non-Ig partners (41.2% vs. 34.0%). There was no evidence of an AID motif cluster at the second hotspot, which could have explained the enrichment for Ig partners and there was no effect of the breakpoint position on patient outcome (Online Supplementary Figure S4E) .
Tandem-duplication breakpoints were enriched at the second hotspot (69.0% of breakpoints) ( Figure 5 and Online Supplementary Figures S7 and S8) as have previously been noted in MM cell lines. 34 Conversely, deletion breakpoints were enriched at the first hotspot (30.5%) and at an additional hotspot centromeric of MYC (chr8:126.3-126.4 Mb). Inversion breakpoints were equally spread across all three hotspots.
By examining histone marks from the U266 cell line and four myeloma samples, for which we generated ChIP-seq histone mark data, there was also a link with accessible chromatin marks (H3K4me1, H3K4me3, H3K27ac and H3K36me3), DNaseI hypersensitivity sites, and all three breakpoint hotspots, indicating that rearrangements may be more likely to happen in highly accessible, transcribed regions ( Figure 5 ). haematologica | 2020; 105(4) 
Disruption of topologically associated domains by MYC rearrangements.
Topologically associated domains (TAD) have been shown to contain DNA elements that are more likely to interact with one another. Disruption of these TAD may bring super-enhancer elements into the same TAD as MYC, resulting in its increased expression. We examined the super-enhancers from the MM.1S cell line, and TAD from RPMI-8226 and U266 cell lines and integrated MYC breakpoints.
On the six frequent MYC translocation partner loci, breakpoints were clustered near to the super-enhancer and within the same TAD as the super-enhancer ( Figure 6 ). At 8q24, the translocation breakpoints, at the two hotspots, were clustered within the TAD containing MYC and PVT1. The resulting rearrangements would bring the super-enhancer from the partner loci adjacent to MYC, resulting in the formation of a Neo-TAD ( Figure 7B ) and overexpression of MYC.
We identified a patient-derived xenograft sample with a t(4;8) that resulted in insertion of three regions of chromosome 4 next to MYC ( Figure 7A ). This resulted in the super-enhancer from PCDH10, defined by the presence of H3K27Ac and MED1 marks, being placed next to MYC, resulting in overexpression. This shows for the first time in a patient sample a rearrangement that confirms the importance of the placing of a super-enhancer next to MYC.
MMEJ drives 8q24 rearrangements in myeloma haematologica | 2020; 105(4) 1061 Lastly, deletions at 8q24 centromeric of MYC are present in 2.9% (36 of 1,249) of samples ( Figure 5 and Online Supplementary Figures S7 and S8) , and most frequently result in contraction of the region bringing NSMCE2 into close proximity of MYC ( Figure 7C ). This interstitial deletion results in TAD disruption, bringing the superenhancer at NSMCE2, present in the cell lines KMS11 and MM.1S, into the same TAD as MYC, resulting in a fused TAD and overexpression of MYC.
8q24 translocations result in increased expression of MYC and PVT1
The biological consequence of rearrangements at 8q24 is thought to be increased expression of MYC, so we examined the available CoMMpass study RNA-sequencing data (Figure 3 ) and a set of microarray data (Online Supplementary Figure S6) , and categorized samples by type and location of breakpoints. In addition to MYC, we examined the expression of other genes in the regions, but only found significant increases in MYC and the non-coding RNA, PVT1 ( Figure 3A-F) , which were associated with particular types of rearrangements. Expression level of these two genes showed a significant but weak correlation (r=0.4, P<0.001).
The six MYC partner loci present in >10 samples (IGH, IGK, IGL, TXNDC5/BMP6, FOXO3 and FAM46C) had significantly higher expression of MYC (P<0.001) and PVT1 (P<0.001) compared to those without rearrangements or less frequent partners ( Figure 3B and E) . Complex rearrangements involving more than five loci also resulted in higher expression of MYC (P<0.001) and PVT1 (P=0.02) compared to those without rearrangements, at levels equivalent to the frequent translocation partners indicating a selection pressure on these six loci for increased MYC expression. There was no difference in expression between samples with breakpoints at the hotspot around MYC or telomeric of MYC ( Figure 3C and F). There was no difference in expression trends between hyperdiploid (Online Supplementary Figure S9 ) and nonhyperdiploid (Online Supplementary Figure S10) subgroups, but a comparison between specific MYC abnormality groups shows that MYC and PVT1 expression is higher in the hyperdiploidy group (Online Supplementary Figure S11 ).
Integration of MYC binding sites with over-expressed genes identifies proliferation markers as key targets
We went on to determine if there is a gene expression signature associated with MYC abnormalities. We compared samples with and without any structural change at 8q24 and adjusted for hyperdiploidy status, as MYC abnormalities were present twice as often in samples with hyperdiploidy (46.0%, 290 of 630) as compared to nonhyperdiploid samples (22.7%, 102 of 449; P<0.001). A total of 121 genes (113 protein-coding and 8 non-coding RNA genes) were significantly de-regulated with a foldchange threshold of 1.8, of which 31.4% (38 of 121) were up-regulated and 68.6% (83 of 121) were down-regulated ( Figure 8A) . No significant pathway enrichment was detected by Gene Ontology Consortium 35 using both PANTHER 36, 37 and Reactome 38 pathway analysis. (For details of each gene see Online Supplementary Table S7 ).
We performed ChIP-seq against c-Myc and determined haematologica | 2020; 105(4) Figure 8B ). The peaks were compared to the 121 genes that were significantly changed in expression ( Figure 8A ). Six genes were in the intersection between over-expressed and significant peaks: HK2, MTHFD1L, SLC19A1, MFNG, SNHG4, GAS5, ( Figure  8C ). Using less stringent ≥1.3 fold-change cut-off that provided 1,801 genes, of which 40.8% (735 of 1,801) were over-expressed, the intersection of over-expressed genes and those with a significant MYC binding peak was 25.3% (186 of 735). At the top of the list of 186 genes ordered by ChIP-seq -log10 P, we detected upregulation of the genes with known or potential oncogenic activity such as genes promoting cell proliferation, tumor growth and/or inhibition of apoptosis (SNHG15, PPAN, MAT2A, METAP1D, MTHFD2, SNHG17), translation factors (EIF3B, EIF4A1, EEF1B2), and genes involved in ribosome biosynthesis (RPL10A, RPL35, RPL23A, RPSA, RPL13, WDR43).
Importantly, we identified HK2 and PVT1 as direct targets of MYC. HK2 is one of the most significant genes detected by ChIP-seq in both cell lines (-log10 P>200) ( Figure 8C ), as well as having the highest fold-change using RNA-sequencing analysis (Online Supplementary  Table S7 ). This gene is an interesting direct target of MYC as it is part of the glucose metabolism pathway and would lead to increased energy metabolism and proliferation. PVT1 showed a smaller fold-change by RNA-sequencing analysis (approx. 1.4) but had a significant c-Myc protein binding site identified by ChIP-seq, meaning that overexpression of PVT1 is likely to be a downstream effect of MYC overexpression. This leads to a positive feedback loop and even higher MYC expression, as PVT1 positively regulates MYC expression. 39 
Discussion
We show that MYC breakpoints in myeloma are clustered in three main hotspots on chromosome 8, one of which is associated with Ig translocations and tandem-MMEJ drives 8q24 rearrangements in myeloma haematologica | 2020; 105(4) In this dataset, we have used 1,267 NDMM patient samples (of which 36.0% had MYC abnormalities) using next generation sequencing consisting of whole genome, exome and targeted panel data. The frequency of MYC abnormalities reported here is higher than previously seen using other techniques, such as karyotyping or fluorescence in situ hybridization (FISH). This is likely due to the increased resolution of sequencing technologies that can identify small insertions or deletions as well as translocations involving infrequent partner chromosomes. In addition, the complexity of breakpoints at 8q24 makes the placement of FISH probes difficult if all abnormalities are to be detected. The scale of this analysis has allowed us to define the molecular breakpoints surrounding MYC with unparalleled accuracy and without technical bias. One of the two rearrangement hotspots involved in inter-chromosomal translocations in MM is also seen in other B-cell malignancies. In Burkitt's lymphoma, two breakpoint clusters within exon 1 and intron 1 of MYC were defined, which corresponds in location to the non-Ig rearrangement hotspot in MM. 26 The same cluster is seen in diffuse large B-cell lymphoma, where other random breakpoints are also seen scattered both centromeric and telomeric of MYC. 25 Both of these studies looked at relatively small numbers of samples (78 and 17, respectively) and used older techniques, such as long distance PCR and FISH, to detect the breakpoints. It may be that there are also other breakpoint hotspots similar to MM in other B-cell malignancies.
The main chromosomal partner to MYC through interchromosomal rearrangements is chromosome 14, specifically the IGH locus. In Burkitt's lymphoma, the IGH-MYC breakpoints on this chromosome lie almost exclusively within the switch regions (87%), upstream of the IGH constant regions. 26 The remaining 13% are within the joining region of the locus. These breakpoints are consistent with the IGH-MYC rearrangement, being a primary event in Burkitt's lymphoma, occurring in 70-80% of patients. 40 In contrast, in MM, we clearly see that IGH-MYC breakpoints within the IGH locus are not in the switch or joining regions; instead, they are spread out across the constant regions of the locus. This spread is distinct from the five common primary translocation breakpoints in MM [t(4;14), t(11;14), etc.] which are restricted to the switch and joining regions. Even those with MYC breakpoints within switch regions (6.9% of IGH-MYC rearrangements) also have primary rearrangements or are hyperdiploid. This indicates that the IGH-MYC rearrangements are secondary events in MM and probably occur through a different molecular mechanism to the primary translocation events. It is known that the primary translohaematologica | 2020; 105(4) 
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C cations in MM, and the IGH-MYC primary events in Burkitt's lymphoma, are mediated by AID and class switch recombination. 2, 4, 41 Therefore, the IGH-MYC rearrangements may occur through an as yet unknown AID-independent mechanism. The mechanism driving MYC rearrangements is likely not to involve NHEJ, which would result in blunt ended rearrangements. 33 We have shown that MYC rearrangements are more likely to have short homologous sequences in common to both partner chromosomes, which is not seen as frequently in the primary IGH translocations. Short homologous sequences are indicative of MMEJ, 42 rather than NHEJ, and result from fork stalling and template switching during DNA replication or through microhomology-mediated break induced repair. 43, 44 The proteins involved in MMEJ include PARP1, Rad50, and Ercc1, whereas MMEJ is inhibited by functional ATM, H2AX, 53BP1, and BRCA1. 42 We have previously shown that mutation of ATM, BRCA1 and other genes involved in DNA homologous recombination are associated with increased levels of loss of heterozygosity in MM patients. 45 It is likely that disruption of this pathway is key to genomic instability and progression of disease.
The non-Ig chromosomal partners of MYC are not random and are known to contain super-enhancer elements. 5, 6 From our analysis of the breakpoints at the most frequent non-Ig locations [6p24.3 (TXNDC5/BMP6), 1p12 (FAM46C), 6q21 (FOXO3)], we show that the breakpoints at these genes are also clustered. The breakpoints are, in general, contained within TAD which are more likely to interact with one another. 46, 47 Each TAD at the partner chromosome contains a super-enhancer and breakpoints rarely fall outside of the TAD. The rearrangements are predicted to result in a changed TAD structure that places MYC in the same domain as the super-enhancer from the partner locus. If breakpoints were to occur outside of the TAD with the super-enhancer, there would be a lower likelihood of it interacting with MYC and expression would not be enhanced.
We identified 149 partner loci for MYC rearrangements, but 67.2% of the samples with translocations involve one of the six main partners. The Ig partners have strong super-enhancers in MM, but there are many other active super-enhancers and so it is likely that these six main partners are constrained by chromatin structure. The breakpoints at 8q24 surround an epigenetically active region, defined by the active chromatin marks H3K27Ac, H3K36me3 and H3K4me1, as well as DNaseI hypersensitivity sites. It may be that epigenetically active, and there-fore accessible, loci are preferred translocation partners, 48, 49 and the nuclear localization of chromosomes may play a part, too. 50 Each of these different rearrangements results in overexpression of MYC. MYC is not the only gene at 8q24, and, indeed, PVT1 is significantly over-expressed in our dataset. PVT1 is a long non-coding RNA and is associated with inhibition of apoptosis and increased proliferation. 51 It has also been shown that PVT1 interacts with MYC, resulting in a stable protein, and that ablation of PVT1 results in diminished tumorigenicity. 52 It may be that the gene complex encompassing MYC and PVT1 is required for oncogenesis and merits further study.
Besides PVT1, we also identified other genes that are direct targets of c-Myc and are over-expressed in 8q24rearranged samples. These included HK2, a key enzyme involved in glucose metabolism. It has previously been shown that silencing of HK2 sensitizes cancer cells to other drugs, and so overexpression of HK2 in MYC-rearranged myeloma may be a key drug resistance mechanism. 53 Additional genes involved in important cellular functions that increase the oncogenic potential of myeloma cells were also identified, such as ribosome biosynthesis and translation initiation; these are likely to contribute to the poor prognosis seen in MYC-rearranged myeloma. 5, 14 Targeting MYC could, therefore, be an effective way to disrupt many essential tumor features in one hit.
This study provides evidence of complex chromosomal rearrangements at 8q24 as a key cause of MYC oncogenic upregulation. Although we found that several MYC abnormalities are associated with prognosis in this dataset, including MYC-IGL and complex translocations, we have previously shown that the association is not independent of other genomic and clinical markers. 54 However, it may be possible that, with longer follow up, MYC abnormalities may be independently associated with overall survival and be a marker of poor outcome. We also show a specific pattern of chromosomal breakpoints suggesting the role of the chromatin landscape in tumorigenesis. The mechanism of DNA breaks clearly differs between MYC rearrangements, resulting from MMEJ rather than NHEJ, and differs in myeloma compared to primary MYC translocations in lymphoma.
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